dd-cfDNA Beyond Rejection: Decoding Molecular Injury in Lung Transplantation
Published 16 June 2026
At their industry symposium at ISHLT2026, Natera highlighted how donor-derived cell-free DNA (dd-cfDNA) not only rules out rejection with high confidence but also detects broader allograft injury. Experts discussed emerging data on EMI, which is strongly linked to poor outcomes, including increased risk of CLAD.
Through the support of Natera, this session is now available for you to view on demand.
Presenters:
- Nirmal S. Sharma, MD, Baylor St. Luke's Medical Center | Houston, TX USA
- Fatima Anjum, MD, MHA, Temple Health | Philadelphia, PA USA
- Holly Keyt, MD, UT Health San Antonio | San Antonio, TX USA
- Jason Li, MD, Mount Sinai | New York, NY USA
The content of this recording was developed entirely by our industry partner, Natera. It is not an official educational program of the ISHLT, and therefore is not eligible for CME under the ISHLT.